Equivir is a combination of myricetin, hesperidin and piperine phenolic flavonoid compounds, being developed by GRDG Sciences for the treatment of various viral infections including influenza (H1N1, H3N2, H5N1, H7N9, Influenza B, Parainfluenza 3), rhinovirus, ebola, dengue virus and coronavirus infection (COVID-2019-infections and Human Coronavirus-A). In preclinical studies, equivir showed enhanced antiviral properties in terms of efficacy in treating influenza, dengue virus and ebola. Preclinical development is underway in the US.
Key Development Milestones
As of February 2020, Equivir demonstrated in vitro efficacy against multiple strains of Influenza (H1N1, H3N2, H5N1, H7N9, Influenza B, Parainfluenza 3), Human Rhinovirus-14, Human Coronavirus-A, and Ebola. The company intends to conduct additional testing for the equivir for the treatment of COVID-2019 infections, the disease caused by the pandemic novel coronavirus SARS-CoV2  .
As of February 2020, Global Biolife has a multiple patents pending worldwide for electrophilically enhanced phenolic compounds for treating inflammatory related diseases and disorders 
In November 2018, Global Biolife has patent US 10 123 991 B2 granted for electrophilically enhanced phenolic compounds for treating inflammatory related diseases and disorders in the US. The patent will expire in May 2036  .